SGLT-2 inhibitors reduce heart failure hospitalization and stroke in patients with acute coronary syndrome

This meta-analysis examined the effects of initiating SGLT-2 inhibitors after acute coronary syndrome in a postacute coronary syndrome setting. The study population consisted of 15114 patients hospitalized for acute coronary syndrome with at least 1 additional risk factor for heart failure hospitalization or adverse cardiovascular outcomes. The interventions included SGLT-2 inhibitors such as empagliflozin and dapagliflozin. The comparator was placebo. The specific dosing protocols for the SGLT-2 inhibitors were not reported in the source data. The follow-up duration was not reported in the source data.

The primary outcome was not reported in the source data. The analysis focused on secondary outcomes including first heart failure hospitalization, stroke, cardiac death, and all-cause mortality. For first heart failure hospitalization, the results showed a significantly reduced risk with a relative risk of 0.78. The 95% confidence interval was 0.66 to 0.92 and the P value was 0.003. For stroke, the risk was significantly reduced with a relative risk of 0.56. The 95% confidence interval was 0.35 to 0.90 and the P value was 0.02.

Regarding cardiac death, a significant reduction was observed with a relative risk of 0.84. The 95% confidence interval was 0.74 to 0.96 and the P value was 0.0009. For all-cause mortality, no significant effect was observed. The source data did not provide specific effect sizes or confidence intervals for all-cause mortality.

Safety and tolerability findings were not reported in the source data. Adverse events, serious adverse events, discontinuations, and overall tolerability were not reported. This lack of safety data is a notable gap in the evidence presented by this meta-analysis.

A key methodological limitation is that the significant reduction in cardiac death was driven mainly by observational studies. This distinction is critical because observational studies are more susceptible to bias and confounding than randomized controlled trials. Consequently, the causal link between SGLT-2 inhibitor use and reduced cardiac death in this specific population remains uncertain based on this evidence alone.

The practice relevance of these findings suggests that the use of SGLT-2 inhibitors as part of postacute coronary syndrome management lowers the risk of heart failure hospitalization, cardiac death, and stroke. However, clinicians must interpret the cardiac death benefit with caution given the reliance on observational data. The evidence does not support a definitive claim of mortality benefit driven by randomized trials in this specific context.

Several questions remain unanswered. The specific dosing regimens and timing of initiation for the SGLT-2 inhibitors were not detailed. The long-term safety profile was not reported. Furthermore, the lack of data on all-cause mortality effect sizes limits the ability to fully assess the overall impact of these agents on survival in this population. Future research should aim to clarify these uncertainties through well-designed randomized trials.